71

is a continuation of U.S. Ser. No. 07/213,671, filed June 30, 1988, now U.S. Pat. No. 5,132,405, which is a continuation of U.S. Ser. No. 07/052,800, filed May 21, 1987, now abandoned.

In the claims:

For the convenience of the examiner, all claims whether or not amended, are presented below.

33. (**Twice Amended**) An isolated polypeptide including an antigen binding site, the polypeptide comprising:

72

(a) two variable domain sequences, each variable domain sequence independently comprising at least one group of three complementarity determining regions (CDRs) interposed between framework regions (FRs), which variable domains are linked to a polypeptide linker to form a single polypeptide chain in which said framework and complementarity determining regions together define a variable region binding domain which can be immunologically reactive with an antigen, and

(b) an amino acid sequence that is a part of said single polypeptide chain, and has a biological activity independent of said immunological reactivity.

NOT SINGLE POLYPEPTIDE CAN BE X-LINKED!

97. (**Amended**) The polypeptide of claim 33, wherein said framework regions are from human immunoglobulin sequences.

73

98. (**Amended**) The polypeptide of claim 33, wherein at least some of said complementarity determining regions are from human immunoglobulin sequences.

99. (**Amended**) The polypeptide of claim 33, wherein said variable domain sequences are from human immunoglobulin sequences.

100. (**Amended**) The polypeptide of claim 33, wherein at least some of said variable domain sequences are from human immunoglobulin sequences.

The amended claims are re-stated below to reflect changes with respect to the last filing.

33. (**Twice Amended**) An isolated polypeptide including an antigen binding site, the polypeptide comprising:

(a) two variable [domains] domain sequences, each variable domain sequence independently [sequence] comprising at least one group of three complementarity determining regions (CDRs) interposed between framework regions (FRs), which variable domains are linked to a polypeptide linker to form a single polypeptide chain in which said framework and complementarity determining regions together define [defining] a variable region binding domain which can be immunologically reactive with an antigen, and

(b) [a third] an amino acid sequence[, being] that is a part of said single polypeptide chain, and has [having] a biological activity independent of said [immunologically] immunological reactivity.

97. (**Amended**) The polypeptide of claim 33, wherein said framework regions are [derived] from human immunoglobulin sequences.

98. (**Amended**) The polypeptide of claim 33, wherein at least some of said complementarity determining regions are [derived] from human immunoglobulin sequences.

99. (**Amended**) The polypeptide of claim 33, wherein said variable [domains] domain sequences are [derived] from human immunoglobulin sequences.

100. (**Amended**) The polypeptide of claim 33, wherein at least some of said variable domain sequences are [complementarity determining regions a derived] from human immunoglobulin sequences.